Amitabh Sagar1, Abhishek Pathak2, Vikas Ambiya3, Nardeep Naithani4, Biju Vasudevan5, Sunil Agrawal6. 1. Associate Professor, Dept of Internal Medicine, Armed Forces Medical College, Pune 40, India. 2. Graded Specialist (Medicine), 166 Military Hospital, C/o 56 APO, India. 3. Graded Specialist (Ophthalmology), Military Hospital, Shillong, India. 4. Professor & Head, Dept of Internal Medicine, Armed Forces Medical College, Pune 40, India. 5. Classified Specialist (Dermatology), Command Hospital (Southern Command), Pune 40, India. 6. ADH, 33 Corps, C/o 99 APO, India.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV) management has witnessed paradigm changes over the past decade. In the early era, Absolute lymphocyte counts (ALC) were used as an inexpensive, indirect marker of immunity status. With time, CD4 lymphocyte counts and HIV RNA levels have become a standard of care for follow up of people living with HIV/AIDS (PLHA). Wide disparities between resource rich and poor countries, rekindles the need for an inexpensive surrogate marker for CD4 lymphocyte counts. Multiple studies in the past including one by Sen S et al, in 2011 did not validate ALC as a surrogate marker of CD4 lymphocyte counts and had recommended a similar study at another centre to validate the same.(1) Recently few publications have suggested that ALC may be used as a proxy marker to CD4 lymphocyte counts in resource poor areas.(2) With this backdrop we decided to evaluate the association if any, of ALC as a surrogate marker to CD4 lymphocyte counts. METHODS: ALC and CD4 lymphocyte counts measurements of 241 patients at our HIV/AIDS referral centre were assessed over a period of 13 months. RESULTS: Pearson correlation coefficient, coefficient of determination and standard statistical methods revealed modest linear correlation between ALC and CD4 lymphocyte counts which was statistically significant but did not have clinical significance. CONCLUSION: We recommend that time has come to call curtains down on ALC as a surrogate marker for CD4 lymphocyte count.
BACKGROUND:Human immunodeficiency virus (HIV) management has witnessed paradigm changes over the past decade. In the early era, Absolute lymphocyte counts (ALC) were used as an inexpensive, indirect marker of immunity status. With time, CD4 lymphocyte counts and HIV RNA levels have become a standard of care for follow up of people living with HIV/AIDS (PLHA). Wide disparities between resource rich and poor countries, rekindles the need for an inexpensive surrogate marker for CD4 lymphocyte counts. Multiple studies in the past including one by Sen S et al, in 2011 did not validate ALC as a surrogate marker of CD4 lymphocyte counts and had recommended a similar study at another centre to validate the same.(1) Recently few publications have suggested that ALC may be used as a proxy marker to CD4 lymphocyte counts in resource poor areas.(2) With this backdrop we decided to evaluate the association if any, of ALC as a surrogate marker to CD4 lymphocyte counts. METHODS: ALC and CD4 lymphocyte counts measurements of 241 patients at our HIV/AIDS referral centre were assessed over a period of 13 months. RESULTS: Pearson correlation coefficient, coefficient of determination and standard statistical methods revealed modest linear correlation between ALC and CD4 lymphocyte counts which was statistically significant but did not have clinical significance. CONCLUSION: We recommend that time has come to call curtains down on ALC as a surrogate marker for CD4 lymphocyte count.
Entities:
Keywords:
CD4 lymphocyte counts; Human immunodeficiency virus; Surrogate marker
Authors: Kathryn Anastos; Yolanda Barrón; Mardge H Cohen; Ruth M Greenblatt; Howard Minkoff; Alexandra Levine; Mary Young; Stephen J Gange Journal: Ann Intern Med Date: 2004-02-17 Impact factor: 25.391
Authors: Kathryn Anastos; Quihu Shi; Audrey L French; Alexandra Levine; Ruth M Greenblatt; Carolyn Williams; Jack DeHovitz; Robert Delapenha; Donald R Hoover Journal: J Acquir Immune Defic Syndr Date: 2004-04-01 Impact factor: 3.731
Authors: Opemipo O Johnson; Daniel K Benjamin; Daniel K Benjamin; Werner Schimana; L Gayani Tillekeratne; John A Crump; Keren Z Landman; Grace D Kinabo; Blandina Mmbaga; Levina J Msuya; John F Shao; Mark E Swai; Coleen K Cunningham Journal: Pediatr Infect Dis J Date: 2009-06 Impact factor: 2.129
Authors: Richard Bedell; Katherine V Heath; Robert S Hogg; Evan Wood; Natasha Press; Benita Yip; Michael V O'Shaughnessy; Julio S G Montaner Journal: Antivir Ther Date: 2003-10
Authors: Bruno Ledergerber; Jens D Lundgren; A Sarah Walker; Caroline Sabin; Amy Justice; Peter Reiss; Cristina Mussini; Ferdinand Wit; Antonella d'Arminio Monforte; Rainer Weber; Gregory Fusco; Schlomo Staszewski; Matthew Law; Robert Hogg; Fiona Lampe; M John Gill; Francesco Castelli; Andrew N Phillips Journal: Lancet Date: 2004 Jul 3-9 Impact factor: 79.321